移植后环磷酰胺改善患者报告结局:BMT CTN 1703 生活质量评估与 2 年结局
BMT CTN 1703 III 期试验的伴随研究评估移植后环磷酰胺(PTCy)联合他克莫司(Tac)和吗替麦考酚酯(MMF)对比 Tac/甲氨蝶呤(MTX)对患者报告结局的影响,PTCy 组 Lee 慢性 GVHD 症状量表评分显著更低(P=0.01),营养和口腔子评分更优(均 P<0.01),2 年无 GVHD 无复发生存(GRFS)PTCy 组 42.4% 对比 Tac/MTX 组 28.8%(P=0.001)。
要点
- PTCy 组 Lee 慢性 GVHD 症状量表总分显著低于 Tac/MTX 组(P=0.01),症状负担更轻
- PTCy 组 Lee 量表营养和口腔子评分均优于 Tac/MTX 组(P<0.01)
- 2 年 GRFS:PTCy 组 42.4% 对比 Tac/MTX 组 28.8%(P=0.001)
核心结论
- PTCy/Tac/MMF 方案在改善无 GVHD 无复发生存的同时,使移植后第一年患者报告的症状负担更低。
研究设计与样本
- BMT CTN 1703 III 期试验的伴随研究,分析英语和西班牙语受试者在基线及移植后第 100、180、365 天的患者报告结局。
主要发现
- PTCy 组 Lee 慢性 GVHD 症状量表评分显著低于 Tac/MTX 组(P=0.01),提示 GVHD 症状负担更低。
- PTCy 组 Lee 量表营养和口腔子评分均优于 Tac/MTX 组(P<0.01)。
- 年龄>65 岁参与者 Lee 量表心理子评分优于较年轻参与者(P=0.003)。
- 出血性膀胱炎症状及 PROMIS 子量表在两组间无显著差异。
- 2 年更新临床终点:PTCy/Tac/MMF 组 GRFS 42.4% 对比 Tac/MTX 组 28.8%(P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant. PRO scores were compared between the arms using inverse probability weighted-independent estimating equation models. The PTCy arm had significantly lower scores on the Lee Chronic GVHD Symptom Scale (P = .01), indicating lower GVHD symptom burden. Lee Scale nutrition and mouth subscores were also better in the PTCy arm compared with the Tac/MTX arm (P < .01 for both). Older participants (age >65 years) reported better Lee Scale psychological subscores than younger participants (P = .003). No significant differences were identified in hemorrhagic cystitis or in the PROMIS subscales between treatment arms. The updated clinical end points at 2 years for the parent trial confirmed that PTCy/Tac/MMF maintained a significant advantage over Tac/MTX in GRFS (42.4% v 28.8%, P = .001). In addition to improved GRFS, patients randomly assigned to the PTCy arm reported lower symptom burden during the first year after transplant.
引用
- Holtan SG, Bolaños-Meade J, Al Malki MM, et al. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025. PMID: 39752608. doi:10.1200/JCO.24.00921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。